テロメラーゼ【telomerase】
テロメラーゼ
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2024/06/25 02:17 UTC 版)
テロメラーゼ (英: telomerase) は、真核生物の染色体末端（テロメア）の特異的反復配列を伸長させる酵素。テロメア伸長のテンプレート（鋳型）となるRNA構成要素と逆転写酵素活性を持つ触媒サブユニットおよびその他の制御サブユニットによって構成されている[1][2][3][4][5]。
- ^ a b c d e f 井出(2006), pp. 1103–4.
- ^ a b Jabion TERT
- ^ a b Jabion TERC
- ^ a b Jabion DKC1
- ^ a b Jabion TEP1
- ^ Hayflick L, Moorhead PS (1961). “The serial cultivation of human diploid cell strains”. Exp Cell Res 25: 585-621. PMID 13905659.
- ^ 東京都老人総合研究所「ヒト胎児肺線維芽細胞（ヘイフリックモデル）」
- ^ GEヘルスケア・ジャパン株式会社「バイオダイレクトメール vol.40 細胞夜話WI細胞〜Hayflick Limit発見の立役者」
- ^ Olovnikov AM (1973). “A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon”. J Theor Biol. 41 (1): 181-90. PMID 4754905.
- ^ a b Greider CW Blackburn EH (1985). “Identification of a specific telomere terminal transferase activity in Tetrahymena extracts”. Cell 43 (2 Pt 1): 405–13. PMID 3907856.
- ^ Szostak JW, Blackburn EH (1982). “Cloning yeast telomeres on linear plasmid vectors”. Cell 29 (1): 245-55. PMID 6286143.
- ^ Greider CW, Blackburn EH (1989). “A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis”. Nature 337 (6205): 331-7. PMID 2463488.
- ^ AFPBB News（2009年10月06日フランス通信社発信ニュース）「ノーベル医学賞、寿命をつかさどるテロメアとテロメラーゼ酵素とは？」
- ^ The Nobel Prize in Physiology or Medicine 2009; The Telomere– Function and Synthesis(pdf)
- ^ Gavory G, Farrow M, Balasubramanian S (2002). “Minimum length requirement of the alignment domain of human telomerase RNA to sustain catalytic activity in vitro”. Nucleic Acids Res. 30 (20): 4470-80. PMID 12384594.
- ^ Gillis AJ, Schuller A, Skordalakes E (2008), “Structure of the Tribolium castaneum telomerase catalytic subunit TERT”, Nature 455 (7213): 633–7, PMID 18758444
- ^ Rouda S, Skordalakes E. (2007), “Structure of the RNA-binding domain of telomerase: implications for RNA recognition and binding”, Structure 15 (11): 1403-12, PMID 17997966
- ^ a b 井出(2006), pp. 1105–9.
- ^ a b c 井出(2006), p. 1110.
- ^ 井出(2006), p. 1109.(fig.30).
- ^ Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. (1995). "Telomere elongation in immortal human cells without detectable telomerase activity." EMBO J. 14(17):4240-8. PMID 7556065
- ^ Henson JD, Neumann AA, Yeager TR, Reddel RR (2002). “Alternative lengthening of telomeres in mammalian cells”. Oncogene 21 (4): 598-610. PMID 11850785.
- ^ a b 清宮(2006), pp. 26–30.
- ^ Asai A, Oshima Y, Yamamoto Y et al. (2003). “A novel telomerase template antagonist (GRN163) as a potential anticancer agent”. Cancer Res 63 (14): 3931-9. PMID 12873987.
- ^ Dikmen ZG, Gellert GC, Jackson S et al. (2005). “In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor”. Cancer Res 65 (17): 7866-73. PMID 16140956.
- ^ Damm K, Hemmann U, Garin-Chesa P et al. (2001). “A highly selective telomerase inhibitor limiting human cancer cell proliferation”. EMBO J. 20 (24): 6958-68. PMID 11742973.
- ^ Shin-ya K, Wierzba K, Matsuo K et al. (2001). “Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus”. J Am Chem Soc. 123 (6): 1262-3. PMID 11456694.
- ^ Tauchi T, Shin-ya K, Sashida G et al. (2006). “Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia”. Oncogene 25 (42): 5719-25. PMID 16652154.
- ^ a b 井出(2006), p. 1101.
- ^ Blasco MA. "Telomeres and human disease: aging, cancer, and beyond." Nat Rev Genet. 2005 Aug; 6(8):611-22. PMID 16136653
- ^ Fossel M (1998 Jun 3). “Telomerase and the aging cell: implications for human health”. JAMA 279 (21): 1732-5. PMID 9624027.
- ^ Tomás-Loba A, Flores I, Fernández-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borrás C, Matheu A, Klatt P, Flores JM, Viña J, Serrano M, Blasco MA. "Telomerase reverse transcriptase delays aging in cancer-resistant mice." Cell. 2008 Nov 14;135(4):609-22 PMID 19013273
- ^ de Magalhaes JP, Toussain O. "Telomeres and telomerase: a modern fountain of youth?" Rejuvenation Res. 2004 Summer; 7(2):126-33 PMID 15312299
- ^ Yamaguchi H, Calado RT, Ly H et al. (2005). “Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia”. New England Journal of Medicine 352 (14): 1413–24. PMID 15814878.
- ^ Zhang A, Zheng C, Hou M et al. (2003). “Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of telomere maintenance in Cri du chat syndrome”. Am J Hum Genet. 72 (4): 940–8. PMID 12629597.
- ^ Yamaguchi(2007), pp. 202–9.
- ^ Yamaguchi(2007), p. 202.
- ^ a b Marrone A, Walne A, Dokal I (2005). “Dyskeratosis congenita: telomerase, telomeres and anticipation”. Curr Opin Genet Dev. 15 (3): 249–57. PMID 15917199.
- ^ Heiss NS, Knight SW, Vulliamy TJ et al. (1998). “X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions”. Nat Genet. 19 (1): 32-8. PMID 9590285.
- ^ Vulliamy T, Marrone A, Goldman F et al. (2001). “The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita”. Nature 413 (6854): 432-5. PMID 11574891.
- ^ Vulliamy TJ, Walne A, Baskaradas A et al. (2005). “Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure”. Blood Cells Mol Dis. 34 (3): 257-63. PMID 15885610.
- ^ Vulliamy TJ, Knight SW, Mason PJ, Dokal I (2001). “Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita”. Blood Cells Mol Dis. 27 (2): 353–7. PMID 11259155.
- ^ Armanios M, Chen JL, Chang YP et al. (2005). “Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita”. PNAS 102 (44): 15960–4. doi:10.1073/pnas.0508124102. PMID 16247010.
[続きの解説]
「テロメラーゼ」の続きの解説一覧
- 1 テロメラーゼとは
- 2 テロメラーゼの概要
- 3 参考文献
「テロメラーゼ」の例文・使い方・用例・文例
固有名詞の分類
- テロメラーゼのページへのリンク
